Literature DB >> 12228243

Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice.

Yan Hu1, Joseph E Ippolito, Emily M Garabedian, Peter A Humphrey, Jeffrey I Gordon.   

Abstract

The features and functions of prostatic neuroendocrine (NE) cells remain ill-defined. Neuroendocrine differentiation (NED) in adenocarcinoma of the human prostate (CaP) is associated with more aggressive disease, but the underlying mediators are poorly understood. We examined these issues in transgenic mice that utilize regulatory elements from the cryptdin-2 gene (Defcr2) to express simian virus 40 large T antigen (TAg) in prostatic NE cells. CR2-TAg mice develop prostatic intraepithelial neoplasia at 8 weeks of age, 1 week after the onset of TAg expression. An invasive phase follows 2-4 weeks later, with lymph node, liver, lung, brain, and bone metastases appearing within 16 weeks. DNA microarray studies revealed 122 mRNAs that were increased >/=2-fold in duplicate assays of 16-week-old CR2-TAg versus normal prostates. Thirty two transcripts encode proteins associated with neurons and endocrine cells (e.g. basic helix loop helix, SRY-related high mobility group box and sine-oculis homeobox transcription factors, Hu RNA-binding proteins, neuronatin, Racgap1, collapsin response mediator protein-1, synaptotagmin-1, proprotein convertase, and secretogranins). Follow-up studies of candidate mediators and biomarkers of differentiation/growth in the microarray data set involved real time quantitative reverse transcriptase-PCR assays of laser capture microdissected NE cells from CR2-TAg prostates plus liver metastases, and immunohistochemical comparisons of transgenic mouse prostates and 35 human CaP samples. Our findings include (a) expression of the bHLH mouse achaete-scute homolog (mASH1) in normal and CR2-TAg NE cells and foci of NED in human CaP, (b) glutamic acid decarboxylase and its product (gamma-aminobutyric acid) in neoplastic NE cells juxtaposed next to cohorts of normal gamma-aminobutyric acid receptor expressing secretory cells (a potential route for paracrine interactions between these two epithelial lineages), and (c) aromatic l-amino-acid decarboxylase, but not its dopamine/serotonin products, in CR2-TAg NE cells and NED. These results underscore the value of CR2-TAg mice for characterizing normal NE cell biology and tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12228243     DOI: 10.1074/jbc.M205784200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer.

Authors:  Chunxiao Wu; Alexander W Wyatt; Anna V Lapuk; Andrew McPherson; Brian J McConeghy; Robert H Bell; Shawn Anderson; Anne Haegert; Sonal Brahmbhatt; Robert Shukin; Fan Mo; Estelle Li; Ladan Fazli; Antonio Hurtado-Coll; Edward C Jones; Yaron S Butterfield; Faraz Hach; Fereydoun Hormozdiari; Iman Hajirasouliha; Paul C Boutros; Robert G Bristow; Steven Jm Jones; Martin Hirst; Marco A Marra; Christopher A Maher; Arul M Chinnaiyan; S Cenk Sahinalp; Martin E Gleave; Stanislav V Volik; Colin C Collins
Journal:  J Pathol       Date:  2012-03-21       Impact factor: 7.996

2.  BMP7 inhibits branching morphogenesis in the prostate gland and interferes with Notch signaling.

Authors:  Irina B Grishina; Sung Yup Kim; Christopher Ferrara; Helen P Makarenkova; Paul D Walden
Journal:  Dev Biol       Date:  2005-12-15       Impact factor: 3.582

3.  A new binding motif for the transcriptional repressor REST uncovers large gene networks devoted to neuronal functions.

Authors:  Stefanie J Otto; Sean R McCorkle; John Hover; Cecilia Conaco; Jong-Jin Han; Soren Impey; Gregory S Yochum; John J Dunn; Richard H Goodman; Gail Mandel
Journal:  J Neurosci       Date:  2007-06-20       Impact factor: 6.167

Review 4.  The genomic revolution and endocrine pathology.

Authors:  Suzana S Couto; Robert D Cardiff
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

Review 5.  Mouse models of prostate cancer: picking the best model for the question.

Authors:  Magdalena M Grabowska; David J DeGraff; Xiuping Yu; Ren Jie Jin; Zhenbang Chen; Alexander D Borowsky; Robert J Matusik
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

6.  A transgenic mouse model of metastatic carcinoma involving transdifferentiation of a gastric epithelial lineage progenitor to a neuroendocrine phenotype.

Authors:  Andrew J Syder; Sherif M Karam; Jason C Mills; Joseph E Ippolito; Habib R Ansari; Vidya Farook; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-30       Impact factor: 11.205

7.  Molecular characterization of the Ggamma-globin-Tag transgenic mouse model of hormone refractory prostate cancer: comparison to human prostate cancer.

Authors:  Alfonso Calvo; Carlos Perez-Stable; Victor Segura; Raúl Catena; Elizabeth Guruceaga; Paul Nguewa; David Blanco; Luis Parada; Teresita Reiner; Jeffrey E Green
Journal:  Prostate       Date:  2010-05-01       Impact factor: 4.104

8.  Mash1 expression is induced in neuroendocrine prostate cancer upon the loss of Foxa2.

Authors:  Aparna Gupta; Xiuping Yu; Tom Case; Manik Paul; Michael M Shen; Klaus H Kaestner; Robert J Matusik
Journal:  Prostate       Date:  2012-10-11       Impact factor: 4.104

9.  Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer.

Authors:  Teresa Chiaverotti; Suzana S Couto; Annemarie Donjacour; Jian-Hua Mao; Hiroki Nagase; Robert D Cardiff; Gerald R Cunha; Allan Balmain
Journal:  Am J Pathol       Date:  2007-12-21       Impact factor: 4.307

10.  Isolation and identification of L-dopa decarboxylase as a protein that binds to and enhances transcriptional activity of the androgen receptor using the repressed transactivator yeast two-hybrid system.

Authors:  Latif A Wafa; Helen Cheng; Mira A Rao; Colleen C Nelson; Michael Cox; Martin Hirst; Ivan Sadowski; Paul S Rennie
Journal:  Biochem J       Date:  2003-10-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.